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Background: There is evidence for augmented processing of pain and impaired endogenous pain inhibition in
Fibromyalgia syndrome (FM). In order to fully understand the mechanisms involved in FM pathology, there is a
need for closer investigation of endogenous pain modulation. In the present study, we compared the functional
connectivity of the descending pain inhibitory network in age-matched FM patients and healthy controls (HC).
We performed functional magnetic resonance imaging (fMRI) in 42 subjects; 14 healthy and 28 age-matched FM
patients (2 patients per HC), during randomly presented, subjectively calibrated pressure pain stimuli. A seed-based
functional connectivity analysis of brain activity was performed. The seed coordinates were based on the findings
from our previous study, comparing the fMRI signal during calibrated pressure pain in FM and HC: the rostral
anterior cingulate cortex (rACC) and thalamus.
Results: FM patients required significantly less pressure (kPa) to reach calibrated pain at 50 mm on a 0–100 visual
analogue scale (p< .001, two-tailed). During fMRI scanning, the rACC displayed significantly higher connectivity to
the amygdala, hippocampus, and brainstem in healthy controls, compared to FM patients. There were no regions
where FM patients showed higher rACC connectivity. Thalamus showed significantly higher connectivity to the
orbitofrontal cortex in healthy controls but no regions showed higher thalamic connectivity in FM patients.
Conclusion: Patients with FM displayed less connectivity within the brain’s pain inhibitory network during
calibrated pressure pain, compared to healthy controls. The present study provides brain-imaging evidence on how
brain regions involved in homeostatic control of pain are less connected in FM patients. It is possible that the
dysfunction of the descending pain modulatory network plays an important role in maintenance of FM pain and
our results may translate into clinical implications by using the functional connectivity of the pain modulatory
network as an objective measure of pain dysregulation.Introduction
FM is a common pain disorder, estimated to affect 2 to 4 %
of the population, out of which 80 % are women [1]. This
multi-symptomatic pain syndrome is characterized by
widespread musculoskeletal pain, stiffness, soft tissue
tenderness, general fatigue and sleep disturbances [2].
Effective treatment for FM is scarce and long-term follow-
up demonstrates that FM is chronic, with recurrent periods
of intensified symptoms and low probability of full recovery* Correspondence: karinj@nmr.mgh.harvard.edu
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reproduction in any medium, provided the or[3]. As a result, FM often has devastating effects on quality
of life, including lost productivity and increased healthcare
costs [4-6]. The strongest precursor to FM is the presence
of long-term localized pain [7], suggesting that FM path-
ology develops over time in exposure to persistent pain. A
better understanding of central pain modulation in FM,
and therefore of its underlying mechanisms, could help to
develop strategies aimed at prevention and treatment.
Accumulated evidence indicates that pain dysregulation
within the central nervous system plays an important role
in the development and maintenance of FM. For instance,
brain imaging studies suggest that FM is associated with 1)
augmented brain responses to experimental pain stimuli
[8,9]; 2) changed resting-state functional connectivity [10];Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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implicated in pain processing [11-13] and 4) altered
function of brain neurotransmission [14-17]. A number of
behavioral studies have suggested that the Descending
Pain Modulatory System (DPMS) is impaired in FM
[18-21]. However, the DPMS hypothesis has been poorly
explored in brain imaging studies. In a previous study, we
provided indirect evidence for DPMS dysfunction in FM
by comparing pain-evoked brain activity in FM patients
and healthy controls during conventional fMRI. Results
showed that FM patients failed to activate the rostral
anterior cingulate cortex (rACC) - a key region for the
descending inhibition of pain [22]. In line with findings
from previous neuroimaging studies [9,23,24], we also
found decreased thalamic activation, indicating altered
regulation of incoming pain signals in FM.
Recently, several fMRI studies have significantly
enhanced our understanding of the intrinsic functional
connectivity underlying pain perception [25,26], pain
modulation [27] and pain pathology [28,29]. In a previous
study [27], we found that key regions for descending
pain modulation, including the rACC, PAG and Rostral
Ventromedial Medulla, were functionally connected
during resting state in healthy individuals; indicating that
functional connectivity could be a useful tool to investigate
the pain modulatory system.
In this study we used connectivity analyses of fMRI data
to investigate the functional connectivity of the rACC and
thalamus during pressure-evoked pain, in both healthy
controls and FM patients. Previous neuroimaging studies
in FM found altered cerebral activity during evoked pain
[8,9,22], suggesting that the functional connectivity
during active processing of pain may better represent the
pathophysiology of FM. We hypothesized that, compared
to healthy controls, FM patients would display less pain-
evoked functional connectivity between our seed regions
(rACC and thalamus) and other nodes in the pain modula-
tory system.
Material and Methods
Participants
A total of 42 female subjects (28 FM patients and 14
healthy controls) were analyzed in the present study.
Patients were recruited as part of a pharmacological
multicenter study (EudraCT # 2004-004249-16). All three
sites – one in England, Sweden and Germany, respectively
- also performed the experiment in healthy controls,
consecutively recruited throughout the study. A total of 92
female FM patients aged 25 to 55 years, mean age 44
(SD=8.2) were enrolled. Of the 92 patients 9 were
excluded from fMRI analyses due to image artifacts or
en passant findings of intracranial anomalies, leaving 83
patients for matching with healthy controls. A total of 14
healthy female controls were available, aged 24 to 48 years,mean age 34 (SD=8.6). Due to the relatively large number
of patients, each healthy control could be age-matched
with two FM patients (n= 28, range 24–48 years, mean 38,
SD=6.8). In cases where there were more than two
patients with the same age, the two patients with the
most similar duration of FM symptoms were chosen. The
study was performed in accordance with the Helsinki
Declaration and was approved by the local Ethical
Committee at each of the three participating sites. All
patients and healthy controls gave written informed
consent. Parts of the present dataset were used in 2
previous publications; see Jensen et al. 2010 [30] where all
92 available FM patients were analyzed, and Jensen et al.
2009 [22], where 11 FM patients and 14 controls from the
present study were included.
Procedure
All subjects were first screened and then scheduled for
one behavioral session and one fMRI session on two
adjacent days. On day one, subjects were familiarized
with the equipment that was used to evoke experimental
pain, calibrated for subjective pain ratings and asked to
fill out self-report questionnaires. FMRI scanning was
performed on day two.
Screening
All subjects were right-handed. The study protocol
required that all medications that could influence pain
perception, including psychopharmacological medications,
were washed out. Patients had to withdraw from all central
nervous system acting therapies, including antidepres-
sants, anticonvulsants, mood stabilizers, opioids, and
narcotic patches, and to discontinue treatment with trans-
cutaneous electrical nerve stimulation, biofeedback, tender
and trigger point injections, acupuncture, and anesthetics.
Required periods off medication were dependent on the
actual pharmacological characteristics to ensure complete
washout. All analgesics were prohibited during the study,
except for paracetamol, dipyrone and nonsteroidal anti-in-
flammatory agents (NSAIDs), which were used as rescue
medications. The rescue medications had to be prescribed
at the lowest available dose and for the shortest period
of time necessary to manage the patient’s acute pain. Use
of any analgesic or narcotic drug had to be discontinued
48 hours prior to the assessments of pain sensitivity.
Zolpidem was allowed for treatment of insomnia. Exclu-
sion criteria included the following: severe psychiatric
illness (including severe melancholic depressive episode);
serious suicide risk; history or behavior that would
prohibit study compliance; history of substance, drug, or
alcohol abuse; heavy cigarette smoking (> 25 cigarettes/
day); presentation of an intracranial anomaly; significant
cardiovascular, pulmonary, gastrointestinal, hepatic, or renal
disease; history of autoimmune disease; current systemic
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current cancer therapy; unstable endocrine disease; severe
sleep apnea; or pregnancy or breastfeeding. FM patients
were mainly recruited from primary care and were
diagnosed according to the 1990 American College of
Rheumatology criteria [2]. All patients had a self-reported
average pain intensity of at least 40 mm on a 100 mm visual
analogue scale (VAS) over the previous week. For healthy
controls, the exclusion criteria included presence and/or
history of any clinical pain problem.
Pain stimulation
Calibration of pain and stimulations during fMRI were
performed using a laptop-controlled tool that delivered
pressure to the right thumbnail. This specially designed
tool, which consists of a plastic piston that applies pressure
via a 1 cm2 hard rubber probe, has been proven effective
in several previous publications [9,31,32]. Calibration was
performed one day before fMRI scanning. Subjects were
instructed to rate the intensity of the pain evoked by each
stimulus by putting a mark on a 0–100 mm horizontal
VAS ranging from “no pain” to “worst imaginable pain”.
Each subject’s pain threshold and tolerance were deter-
mined in an ascending series of pressures, using 50 kPa
increments (tolerance was determined as the first pressure
where the patient rated> 60 mm VAS). These values were
then used to create a randomized series of five different
pressure intensities within the range of each subject’s
threshold and tolerance. For example, if the pain threshold
was represented by 200 kPa, and the maximum pain rating
by 600 kPa, the randomized series would consist of
pressures of 200 kPa, 300 kPa, 400 kPa, 500 kPa and 600
kPa. In total, 15 stimuli were delivered in a randomized
order at 30 seconds intervals. The duration of each pres-
sure stimulus was 2.5 seconds. Pain ratings from the
randomized series were used to calculate each subject’s
calibrated pressure at 50 mm VAS. This calibrated pres-
sure was used during fMRI scanning on the following day.
Imaging with fMRI
Images were collected using three different 1.5 Tesla
scanners: in London a General Electric HDx scanner was
used, in Stockholm a General Electric Twinspeed Signa
Horizon, and in Cologne a PHILIPS scanner was used.
Multiple T2*-weighted single-shot gradient echo EPI
sequences were used to acquire blood oxygen level
dependent (BOLD) contrast images. The following para-
meters were used: repetition time: 3000 ms (35 slices
acquired), echo time: 40 ms, flip angle: 90 degrees, field
of view: 24 × 24 cm, 64 × 64 matrix, 4 mm slice thickness
with 0.4 mm gap and sequential image acquisition order.
In the scanner, cushions and headphones were used to
reduce head movement and dampen scanner noise.
Placing a blank screen in front of the patient’s field ofview from inside the scanner minimized visual distrac-
tion during scans.
Two types of stimulations were used during the func-
tional scans: individually calibrated painful pressure, repre-
senting each subject’s 50 mm VAS, and a non painful
pressure perceived as light touch, representing 0 mm VAS.
All stimulations were randomly jittered over the scanning
time, preventing subjects from anticipating the onset time
and event type. The time interval between consecutive
events was randomized with a mean stimulus onset
asynchronicity (SOA) of 15 seconds (range 10–20
seconds). The total duration of the scans was approxi-
mately 35 minutes. Before scanning, subjects were
instructed to focus on the pressures on the thumb and not
to use any distraction or coping techniques.
In addition to the functional scans, high-resolution T1-
weighted structural images were acquired in coronal orien-
tation for anatomical reference purposes and screening
for cerebral anomalies. Parameters were: Spoiled
Gradient Recalled 3D sequence, repetition time: 24 ms,
echo time: 6 ms, flip angle 35 degrees with a voxel size
of 0.9 × 1.5 × 0.9 mm3.
The scanning procedure was standardized between sites
by the use of written manuscripts for the oral instructions
as well as practical training for all investigators involved
in the study. In order to ensure calibrated experimental
procedures and scanner settings, several visits were done
at the three sites by a central coordinator.
Self-report measures
The day before fMRI-scanning, all patients used a
0–100 mm VAS to rate their average clinical pain during
the previous week and their current pain. Additionally,
patients completed the Fibromyalgia Impact Questionnaire
(FIQ); a 20-question questionnaire that assesses the overall
symptom severity in patients with FM [33]. A high score
on the FIQ corresponds to high self-reported FM severity.
Analysis of behavioral data
The differences between FM patients and healthy controls
regarding age and pressure pain sensitivity were assessed
using two independent samples t-tests (two-tailed). A
polynomial regression was used to determine each indivi-
dual’s representation of VAS 50 mm, built on the 15
ratings from the randomized series of thumb pressures.
The SPSS statistics software, version 18, was used for
statistical analyses of behavioral data.
Functional connectivity analysis
The connectivity fMRI analyses were performed in line with
the methods previously described by our group [26,27,34]
and other groups [35,36]. In brief, functional data was
preprocessed to decrease image artifacts, between-slice
timing differences, and differences in odd/even slice
Figure 1 Pressure needed to evoke the same subjective levels
of pain in FM patients and controls. A total number of 15 thumb-
pressures were given in order to calculate the pressure that would
represent a pain intensity of 50 mm VAS (0–100). A two-samples t-test
confirmed that patients required significantly less pressure (kPa) than
controls in order to reach VAS 50 mm; p< .001, two-tailed.
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Gaussian kernel of 6 mm full-width at half-maximum
and temporally filtered (0.009 Hz< f< 0.08 Hz). Several
spurious or nonspecific sources of variance were removed
by including the following variables in the overall statistical
model: 1) six movement parameters computed by rigid
body translation and rotation during preprocessing, 2) mean
whole brain signal, 3) mean brain signal within the lateral
ventricles, and 4) the mean signal within a deep white
matter ROI. Inclusion of the first temporal derivatives of
these regressors within the linear model accounted for the
time-shifted versions of spurious variance. The functional
connectivity analysis produced coefficients for each seed-to-
voxel correlation, and Fisher’s r-to-z transformation was
used to convert these correlation maps into z maps. Group
effects were tested with random-effects analyses using
Matlab 7 (Mathworks) and the Statistical Parametric Map-
ping 5 software (SPM5) (http://www.fil.ion.ucl.ac.uk/spm/).
Two separate one-sample t-tests were performed for the
rACC and thalamus, assessing the connectivity between the
seeds and the rest of the brain in FM patients (n=28) and
healthy controls (n=14), respectively. Differences in rACC
and thalamus connectivity between FM patients and healthy
controls were assessed by two separate two-sample t-tests.
The two seeds used in this study were 1) the rACC, cen-
tered at x=8, y =46, z= 4 (Montreal Neurological Institute
[MNI] coordinates) with a 2 mm radius, and 2) the
thalamus, centered at x=−14, y=−34, z=12 MNI with a
2 mm radius. The coordinates were based on the results
from a previous publication where we compared the
pain-evoked fMRI signal in FM patients and healthy
controls [22].
According to our hypothesis and previous studies of
the DPMS [37], the PAG/brain stem [38], amygdala
[39], nucleus accumbens [40], hippocampus [41], and
prefrontal cortex [42] were defined as regions of inter-
est. For predefined anatomical regions of interest
(ROI’s), the statistical threshold was set at voxel-wise
p< .005, uncorrected, with a minimum cluster size of
20 contiguous voxels. For all other brain regions, a
threshold of voxel-wise p< .05, corrected for multiple
comparisons, was used.Results
Behavioral results
Each healthy control subject (n= 14) was age-matched
with two FM patients (n= 28). A two-sample t-test
validated that there was no significant difference in age
between the two groups (t =−1.59, p=0.126). In accord-
ance with our previous findings, the sensitivity to pressure
was significantly higher in FM patients, represented by
lower amounts of pressure required to evoke pain at
50 mm VAS (t = 4.14, p< .001) (see Figure 1).Neuroimaging results
rACC functional connectivity
A one-sample t-test for FM patients only (n= 28), demon-
strated significant functional connectivity between the
seed located in the rACC and the contralateral rACC and
medial prefrontal cortex (MPFC), an area which was
predefined as an ROI. Also, there was significant connect-
ivity between the rACC and the precuneus and occipital
cortex (for all results see Table 1; ROI results indicated in
italics). A one-sample t-test for healthy controls demon-
strated similar functional connectivity between the seed
region in the rACC and the MPFC, precuneus and the
parietal cortex. A direct comparison between the healthy
controls and FM patients (two sample t-test) revealed that,
compared to FM patients, the rACC of healthy controls
had significantly higher connectivity to the left amygdala,
bilateral hippocampi, and the brainstem (Figure 2). There
were no regions where FM patients showed higher rACC
connectivity than the controls. For all rACC connectivity
results, see Table 2; ROI results indicated in italics. In an
exploratory analysis of our data using a lower threshold for
continuous voxels (5 voxels instead of 20 voxels), we found
that the RVM, a key region receiving projections from the
PAG, showed higher rACC connectivity in healthy controls,
compared to FM patients (RVM, p< .005, t = 3.13, 8 voxels,
MNI coordinates: x =−2, y=−18, z =−38).
Thalamic functional connectivity
A one-sample t-test for FM patients only, demonstrated sig-
nificant functional connectivity between the seed located in
the thalamus and the contralateral thalamus. A one-sample
8 min fMRI run (x 2) A 
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Figure 2 Experimental pain paradigm and functional
connectivity results. The schematic illustration (A) represents the
experimental pressure pain paradigm used during fMRI scanning.
Calibrated painful pressures (long lines), representing 50 mm VAS,
and non-painful pressures (short lines) were randomly delivered to
the thumbnail during 2 adjacent 8 minute runs with 20 painful and
10 non-painful stimuli in each run. Functional connectivity results for
the rACC seed (B) revealed incraesed connectivity to the amygdala
(peak coordinate x =−14, y = 0, =− 16) and a cluster encompassing
the brainstem/PAG/hippocampus (peak coordinate x = 12, y = 24,
z =−12) in healthy controls, comapred to FM patients. Functional
connectivity results for the thalmaus seed (C) revealed increased
connectivity to the OBFC (peak coordinate x =−34, y = 50, z =−18) in
healthy controls, compared to FM patients. All anatomical locations
are given in Montreal Neurological Institute coordinates (MNI).
Table 1 Subjects’ characteristics
Variable FM patients(n= 28) Controls(n = 14) t-score p-value
Age (years) 37.8 (6.8) 33.6 (8.6) −1.59 0.126
Pressure at VAS 50 mm (kPa) 333.7 (129.8) 572.4 (195.1) 4.14 0.001*
Duration of FM symptoms (months) 123.8 (76.8) Na
Weekly pain intensity (VAS mm) 72.3 (13.3) Na
Current pain intensity (VAS mm) 61.4 (22.1) Na
FIQ score 71.0 (12.6) Na
*significant at p< .001.
The mean value and Standard Deviation (SD) is given for each variable. For the variables ‘Age’ and ‘Pressure at VAS 50 mm’, the t-score and p-value from an
independent samples t-test is also listed.
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connectivity between the seed region in the thalamus and
the contralateral thalamus as well as the orbitofrontal cortex
(OBFC). In a direct comparison between healthy controls
and FM patients (two sample t-test), the thalamus showed
significantly higher connectivity to the OBFC in healthy
controls. There were no significant regions outside of the
predefined ROI’s and no regions showed higher thalamus
connectivity in FM patients, compared to controls. For all
thalamic connectivity results, see Table 2.Discussion
In this study, we investigated the differences in functional
brain connectivity between FM patients and matched
healthy controls during intermittent application of pres-
sure pain. The results revealed that healthy controls had
higher rACC connectivity to the bilateral hippocampi,
amygdala, brainstem and RVM; regions highly involved
in the descending modulation of pain. Additionally, we
found that healthy controls displayed higher connectivity
between the thalamus and the OBFC, a cortical region
that plays an important role in endogenous modulation of
pain and emotions [43]. Hence, the present neuroimaging
study provides evidence for lower functional connectivity
within the pain inhibitory network of the brain in patients
with FM.rACC connectivity
In a previous study, we found that patients with FM failed
to recruit the rACC during evoked pressure pain [22].
Using the same region as seed for the present connectivity
fMRI analysis, we found that healthy controls displayed
higher rACC connectivity than FM patients to the
hippocampus, a cluster that extended into the PAG area of
the brainstem. It is well known that descending inhibitory
pathways in the brain play a crucial role in pain modula-
tion. The PAG receives direct projections from regions
within the limbic forebrain such as ACC and the amygdala
[37,39,44,45] and can modulate pain perception through
brainstem structures, such as the Rostral Ventromedial
Medulla (RVM), that directly communicate with nociceptive
Table 2 Functional connectivity results in patients with FM and healthy controls
rACC seed: FM patients only (n = 28)(MNI: x = 8, y = 46, z = 4) Maximum voxel Clustersize Maximumt-score Clusterp-value
rACC/Medial prefrontal cortex −8, 46, 4 16513 33.65 0.000**
Precuneus 6, −60, 26 2719 5.45 0.000**
Occipital cortex 44, −74, 32 611 4.78 0.000**
Occipital cortex −44, −72, 38 516 4.39 0.001**
rACC seed: Healthy controls only (n =14)
rACC/Medial prefrontal cortex −8, 46, 4 7122 22.69 0.000**
Posterior Cingulum/Precuneus 2, −40, 38 4180 6.40 0.000**
Parietal/Angular cortex −56, −60, 22 1020 5.62 0.000**
Parietal/Angular cortex 46, −70, 30 693 5.08 0.000**
rACC seed: FM patients>Healthy controls
No significant regions
rACC seed: Healthy controls> FM patients
Amygdala/Parahippocampal −14, 0, −16 60 4.33 0.007*
Hippocampus −20, −24, -12 51 4.23 0.009*
Brainstem/PAG/Hippocampus 12, -24, -12 32 3.61 0.018*
Thalamus seed: FM patients only (n = 28)
(MNI: x =−14, y =−34, z = 12)
Thalamus 14, −34, 12 5523 30.91 0.000*
Thalamus seed: Healthy controls only (n =14)
Thalamus 14, −34, 12 989 21.81 0.000**
Orbitofrontal cortex −34, 50, −18 220 4.49 0.047**
Thalamus seed: FM patients>Healthy controls
No significant regions
Thalamus seed: Healthy controls> FM patients
Orbitofrontal cortex −22, 54, −17 50 3.79 0.008*
** whole brain corrected for multiple comparisons * cluster corrected for multiple comparisons.
Brain regions exhibiting significant functional connectivity with the seed regions rACC and thalamus, respectively, during calibrated pressure-evoked pain (n = 42).
The seed regions, together with the PAG, amygdala, Nucleus Accumbens, hippocampus and prefrontal cortex, were considered regions of interest (ROI’s) and are
marked in italics. The exact anatomical locations (x, y, z) are given in MNI coordinates. All results are corrected for multiple comparisons.
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exploratory analysis of our data, using a lower threshold for
continuous voxels, we found that the RVM had higher
rACC connectivity in healthy controls, compared to FM.
Given the crucial role of the rACC-PAG-RVM network in
pain inhibition [38], our findings provide neuroimaging
evidence for dysfunction of descending pain inhibition in
FM. It is important to note that some brain structures, such
as the ACC, may be divided in sub-regions that serve differ-
ent aspects of pain processing [46], and therefore a region
can sometimes be associated with increases or decreases in
response to pain modulation [47], depending on the exact
anatomical location and experimental paradigm. Recently
published animal studies found augmented synaptic trans-
mission in the ACC in response to long-term exposure to
peripheral pain [48] and there is evidence suggesting that
the rACC is required for the reward associated with pain
relief [49]. Activation of the rostral ACC in humans has been
demonstrated during inhibition of pain [50,51], whereasactivation of the more posterior parts of the ACC has been
associated with increased pain affect [52-54] in humans.
The role of the hippocampus in pain modulation is
less explored but we speculate that the connectivity
between the rACC and the hippocampus is likely
related to the aversive drive and motivational dimension
of pain [41,55]. For example, increased activation of the
hippocampus has been reported in response to anxiety-
induced exacerbation of pain [41] and nocebo-induced
hyperalgesia [56]. It is possible that the relatively lower
connectivity between the rACC and the hippocampus in
FM patients represents an attenuated defensive response
to pain. Similar to reports of lower opioid binding
potentials in FM [14], it is possible that the constantly
ongoing nociceptive activity in patients with FM causes a
ceiling effect for homeostatic pain control, expressed as
relatively lower connectivity between pain defensive
regions like the rACC and the hippocampus, in response
to experimental pain.
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rACC, hippocampus and PAG, control subjects showed
significantly higher connectivity between the rACC and
bilateral amygdalae, a limbic structure with direct projec-
tions to the PAG [37]. Previous studies found that the
amygdala is highly involved in opioid-dependent analgesia
and has been described as a crucial subcortical node for
endogenous pain inhibition [57]. In line with the proposed
role of the hippocampus, the activation of amygdala in
relation to pain is proposed to represent a defensive
mechanism that contributes to the recruitment of
descending inhibition [50]. Thus, the reduced connectivity
between the rACC and amygdala in FM patients may
indicate a weakened defensive response to pain stimuli,
compared to healthy controls.
In one of our previous studies [30], including 92 FM
patients, we investigated the impact of depression and
anxiety on cerebral pain processing in FM, not including
any healthy controls. We found no difference in pain
ratings or cerebral processing in patients with high depres-
sion and anxiety, suggesting that experimentally evoked
pain in FM patients is not confounded by comorbid
affective symptoms. The results from the present study
are derived from the same patient cohort but concerns
comparisons between FM patients and healthy controls,
using connectivity analyses, which is different from any of
our previous studies. However, our previous results may
suggest that the present study is not confounded by
patients’ affective symptoms.
Thalamus connectivity
There is increasing evidence for altered thalamic function
in pain patients with chronic pain such as neuropathic
pain [58,59] and FM [9,23,24]. Previous literature suggests
that lowered thalamic function in FM patients represents a
ceiling effect of descending pain inhibition [9] maintained
by the persistent excitatory input of pain signals. Support
for this mechanism was found in a study where
normalization of reduced thalamic activity was seen in
response to analgesic treatment (nerve blockade) in
patients with peripheral neuropathic pain [58]. When
comparing the functional connectivity between FM
patients and controls, using the thalamus as a seed, we
found significantly higher connectivity between the
thalamus and the lateral OBFC in healthy controls. This
finding supports the general idea that chronic pain alters
the thalamocortical connections, causing a disruption of
thalamic feedback and the view of chronic pain as thala-
mocortical dysrhythmia [28].
The OBFC has been proposed to be involved in sensory
integration, reward processing, decision-making and
expectation [60]. A meta-analysis of previously published
imaging data revealed that the medial part of the OBFC is
related to reward whereas the lateral areas are morerelated to evaluation of noxious events and motivation to
act upon these [61]. In a recent pain study, the OBFC was
associated with reduction in pain unpleasantness after
meditation training [62], indicating OBFC involvement
in the evaluation of incoming pain signals. Moreover the
lateral OBFC is central for placebo analgesia (compared to
opioid analgesia) [42] and for anticipation of pain relief
[63], furthering the notion that the OBFC plays an essen-
tial role in evaluation and inhibition of pain. However,
there are also studies suggesting that the OBFC inhibits
pain through neural projections that do not require
conscious evaluation [64], arguing against the cognitive
role of OBFC in pain inhibition. This alternate theory
suggests that the OBFC is part of a functionally connected
network that inhibits pain through homeostatic regulation
of nociceptive input and endogenous inhibition [65].
Nevertheless, we believe that the reduced functional con-
nectivity between the thalamus and OBFC in FM patients
reflects lower function of pain regulation, possibly acting
through a combination of cognitive evaluative processes
and homeostatic control. A previous neuroimaging study
by Guedj et al. [66], found that FM patients had lowered
resting state perfusion of the prefrontal cortex, supporting
our findings of impaired connectivity between crucial
nodes of the pain inhibitory network of FM patients.Limitations
Due to the uneven number of FM patients and healthy
controls available for this study, we chose to match each
healthy control (n = 14) with two FM patients (n = 28).
We estimate that the benefit of increasing our power
by matching two patients per control, instead of one, is
larger than the risk of getting unfair variance estimations
for the two groups.
In the present study, we used subjectively calibrated
pressure stimuli during fMRI scans, leading to matched
levels of experienced pain in FM patients and controls. As
a result, the pressure needed to evoke pain was signifi-
cantly different for FM patients and controls and could
possibly affect some aspects of our results. It is possible,
but unlikely, that certain parts of the central nervous
system can detect information about absolute stimulus
magnitudes and thereby confound the comparison
between FM patients and controls.Conclusion
In summary, our study indicates that FM patients display
less functional connectivity between areas involved in pain
inhibition compared to healthy controls during intermit-
tent pressure pain administration. Our results suggest
tha the dysfunction of the DPMS, a crucial homeostatic
modulator of pain, plays an important role in maintenance
of FM pain. These results may translate into clinical
Jensen et al. Molecular Pain 2012, 8:32 Page 8 of 9
http://www.molecularpain.com/content/8/1/32implications by using the functional connectivity of DPMS
as an objective measure of pain dysregulation.
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